{
    "clinical_study": {
        "@rank": "8318", 
        "arm_group": [
            {
                "arm_group_label": "Onabotulinum Toxin A", 
                "arm_group_type": "Active Comparator", 
                "description": "One side of the face will be randomized to receive Onabotulinum Toxin A injections in the forehead and glabellar region of the face."
            }, 
            {
                "arm_group_label": "Incobotulinum Toxin A", 
                "arm_group_type": "Active Comparator", 
                "description": "The other side of the face will be randomized to receive Incobotulinum Toxin A injections in the glabellar and forehead region of the face."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the effectiveness of Botox\u00ae (Onabotulinum Toxin A)\n      versus Xeomin\u00ae (incobotulinum toxin A) for the treatment of forehead and glabellar (vertical\n      lines between the eyebrows) wrinkles."
        }, 
        "brief_title": "A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Wrinkles", 
        "detailed_description": {
            "textblock": "Subjects will be screened, photographed, assessed, and randomized to be injected with\n      onabotulinum toxin A on one side and incobotulinum toxin A on the other side during their\n      first clinic visit. Subjects will return for a 2 week, 2 month, 3 month, 4 month, 5 month,\n      and 6 month follow-up to have photographs taken by the unblinded research assistant at\n      relaxed and full contraction.\n\n      This study is a pilot study designed to determine feasibility of these procedures."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Females and males\n\n          2. In good health\n\n          3. Is 20-65 years of age\n\n          4. Has static and moderate dynamic forehead/glabellar wrinkles\n\n          5. Has willingness and the ability to understand and provide informed consent and\n             communicate with the study staff\n\n        Exclusion Criteria:\n\n          1. Pregnant or lactating\n\n          2. Younger than 20 or older than 65 years of age\n\n          3. Has received the following treatments in the forehead or glabellar region:\n\n               1. botulinum toxin injections in the past 6 months\n\n               2. ablative laser procedure in the past 6 months\n\n               3. radiofrequency device treatment in the past 6 months\n\n               4. ultrasound device treatment in the past 6 months\n\n               5. medium to deep chemical peel in the past 6 months\n\n               6. temporary soft tissue augmentation material in the area to be treated in the\n                  past year\n\n               7. semi-permanent soft tissue augmentation material in the area to be treated in\n                  the past 2 years\n\n               8. permanent soft tissue augmentation material in the area to be treated\n\n          4. Is planning to receive within the next 6 months, any cosmetic procedure (such as any\n             chemical peels, botulinum toxin injections, ablative or non-ablative laser\n             procedures, filler injections, radiofrequency procedures, dermabrasion, ultrasound\n             and face lifting procedures) in the forehead or glabellar region.\n\n          5. Is planning to use tretinoin or retinoic acid in the next 6 months\n\n          6. Has an active infection in the forehead or glabellar region (excluding mild acne)\n\n          7. Is allergic to cow's milk protein\n\n          8. Is allergic to albumin\n\n          9. Taking aminoglycoside\n\n         10. Is currently using anticoagulation therapy\n\n         11. Has a history of bleeding disorders\n\n         12. Has a mental illness\n\n         13. Unable to understand the protocol or to give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019004", 
            "org_study_id": "STU83962"
        }, 
        "intervention": [
            {
                "arm_group_label": "Onabotulinum Toxin A", 
                "intervention_name": "Onabotulinum Toxin A", 
                "intervention_type": "Drug", 
                "other_name": "Botox"
            }, 
            {
                "arm_group_label": "Incobotulinum Toxin A", 
                "intervention_name": "Incobotulinum Toxin A", 
                "intervention_type": "Drug", 
                "other_name": "Xeomin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Botulinum Toxins, Type A"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 23, 2013", 
        "location": {
            "contact": {
                "email": "research.nuderm@norhtwestern.edu", 
                "last_name": "Emily Poon, PhD", 
                "phone": "312-695-4761"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60611"
                }, 
                "name": "Northwestern University Department of Dermatology"
            }, 
            "investigator": {
                "last_name": "Murad Alam, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Forehead/Glabellar Rhytide Complex With Onabotulinum Toxin A Versus Incobotulinum Toxin A Injection: A Split-face, Double-blinded, Randomized Control Trial", 
        "overall_contact": {
            "email": "research.nuderm@northwestern.edu", 
            "last_name": "Emily Poon, PhD", 
            "phone": "312-695-4761"
        }, 
        "overall_official": {
            "affiliation": "Northwestern University", 
            "last_name": "Murad Alam, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Two blinded dermatologists will rate each photograph of each subject at baseline and at month 6. The glabellar wrinkle rating is:\n0: no facial wrinkles\nmild facial wrinkles\nmoderate facial wrinkles\nsevere facial wrinkling", 
                "measure": "Change in glabellar wrinkle score from baseline to 6 months for botox vs. xeomin", 
                "safety_issue": "No", 
                "time_frame": "At baseline and at 6 months"
            }, 
            {
                "description": "Two blinded dermatologists will rate each photograph of each subject at baseline and at month 6. The forehead wrinkle Merz rating is:\n0: no wrinkles\nminimal wrinkles\nmild wrinkles\nmoderate wrinkles\nsevere wrinkles", 
                "measure": "Change in forehead wrinkle score from baseline to 6 months for botox vs. xeomin", 
                "safety_issue": "No", 
                "time_frame": "At baseline and at 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019004"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Northwestern University", 
            "investigator_full_name": "Murad Alam", 
            "investigator_title": "Professor in Dermatology, Otolaryngology - Head and Neck Surgery, and Surgery-Organ Transplantation", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Northwestern University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Northwestern University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}